Clinical significance of peripheral TCR repertoire profiling

Immune checkpoint inhibitors have significant clinical benefit for a subset of patients with gastrointestinal cancers. However, it is difficult to predict which patients will respond to immune therapy or induce immune-related adverse events (irAEs). This study was initiated to determine if peripheral TCR (T-cell receptor) repertoire profiling could predict the clinical efficacy of anti-PD-1 treatment, while also predict adverse events.